Vyriad
Biotechnology ResearchMinnesota, United States51-200 Employees
Vyriad is a Rochester, Minnesota-based biotechnology research company focused on developing targeted genetic therapies by delivering genes to specific cells through engineered viral delivery systems. This targeting approach supports oncolytic virotherapy, in vivo gene therapies, and gene editing applications, with the aim of treating cancer with precision. The company advances its therapies by testing oncolytic viruses as monotherapies and in combination with immuno-oncology drugs through early-stage clinical programs, collaborating with leading research institutions. The company's Phase 1-2 trials are active in multiple cancer types, including non-small cell lung cancer, squamous cell carcinoma of the head and neck, metastatic colorectal cancer, breast cancer, and bladder cancer. Vyriad maintains clinical research collaborations with Regeneron, Mayo Clinic, and other leading research and medical institutions. At ASH 2025, Vyriad presented data on its lead in vivo CAR T candidate VV169, highlighting progress toward future clinical development.
1-888-653-2347 
support@leadiq.com 
